Brief: Cns Pharmaceuticals Says University Research Confirms Active Compound In WP1122 Completely Prevents Coronavirus Replication In Vitro

CNS Pharmaceuticals

13/04/2020 14:22

April 13 (Reuters) - CNS Pharmaceuticals Inc  CNSP.O :
    * CNS PHARMACEUTICALS - ANNOUNCES INDEPENDENT UNIVERSITY
RESEARCH
CONFIRMS ACTIVE COMPOUND IN WP1122 COMPLETELY PREVENTS
CORONAVIRUS REPLICATION IN VITRO
    * CNS PHARMACEUTICALS - WP1122 IS SUBJECT TO DEVELOPMENT
AGREEMENT
WITH WPD PHARMACEUTICALS
    * CNS PHARMACEUTICALS - TO RECEIVE 50% OF NET SALES ON
RESULTING
ANTI-VIRAL COMMERCIAL PRODUCTS, INCLUDING WP1122, IN CERTAIN
INTERNATIONAL MARKETS

Source text for Eikon:  ID:nPn6ZhQ2Ja 
Further company coverage:  CNSP.O 

 ((Reuters.Briefs@thomsonreuters.com;))